RecruitingNot ApplicableNCT06585852
Efficacy of Xenograft Alone or Mixed With Arginyl-Glycyl-Aspartic Acid (RGD) in Horizontal Ridge Augmentation With Split-crest Technique for Implant Placement
Efficacy of Xenograft Alone or Mixed With Arginyl-Glycyl-Aspartic Acid (RGD) in Horizontal Ridge Augmentation With Split-crest Technique for Implant Placement. A Randomized Clinical Trial
Sponsor
Al-Azhar University
Enrollment
18 participants
Start Date
Aug 1, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The aim of the present study is to evaluate the efficacy of xenograft alone or xenograft mixed with Arginylglycylaspartic acid (RGD) , in horizontal ridge augmentation with split-crest technique, for implant placement.
Eligibility
Min Age: 18 YearsMax Age: 30 Years
Inclusion Criteria4
- Adults (age 18-30) exhibiting initial insufficiently bone width.
- Patients with good oral hygiene.
- Patients must be free from systemic diseases that may influence the outcome of the therapy.
- Patients with bony horizontal defects alone, Class III \& IV.
Exclusion Criteria4
- Heavy smokers.
- Patient treated by immunosuppressive chemotherapy or radio therapy,
- Allergy to any material or medication used in the study.
- Pregnant females.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGRGD
Study group main material
DRUGXenograft
Scaffold material of choice
PROCEDURESplit crest technique
Piezoelectric surgery
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06585852